Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.
Dummer R, Beyer M, Hymes K, Epping MT, Bernards R, Steinhoff M, Sterry W, Kerl H, Heath K, Ahern JD, Hardwick JS, Garcia-Vargas J, Baumann K, Rizvi S, Frankel SR, Whittaker SJ, Assaf C. Dummer R, et al. Leuk Lymphoma. 2012 Aug;53(8):1501-8. doi: 10.3109/10428194.2012.656625. Epub 2012 Feb 13. Leuk Lymphoma. 2012. PMID: 22239668 Clinical Trial.
Vorinostat in solid and hematologic malignancies.
Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM, Garcia-Vargas J, Sanz-Rodriguez C, Rizvi S. Siegel D, et al. J Hematol Oncol. 2009 Jul 27;2:31. doi: 10.1186/1756-8722-2-31. J Hematol Oncol. 2009. PMID: 19635146 Free PMC article. Review.
Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
Dreyling M, Santoro A, Mollica L, Leppä S, Follows G, Lenz G, Kim WS, Nagler A, Dimou M, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Munoz J, Rodrigues L, Hiemeyer F, Miriyala A, Garcia-Vargas J, Childs BH, Zinzani PL. Dreyling M, et al. Am J Hematol. 2020 Apr;95(4):362-371. doi: 10.1002/ajh.25711. Epub 2020 Jan 16. Am J Hematol. 2020. PMID: 31868245 Free article.
Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies.
Gambacorta MA, Valentini V, Coco C, Morganti AG, Smaniotto D, Miccichè F, Mantini G, Barbaro B, Garcia-Vargas JE, Magistrelli P, Picciocchi A, Cellini N. Gambacorta MA, et al. Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):139-48. doi: 10.1016/j.ijrobp.2004.01.051. Int J Radiat Oncol Biol Phys. 2004. PMID: 15337549 Clinical Trial.
Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.
Fukuhara N, Maruyama D, Hatake K, Nagai H, Makita S, Kamezaki K, Uchida T, Kusumoto S, Kuroda J, Iriyama C, Yanada M, Tsukamoto N, Suehiro Y, Minami H, Garcia-Vargas J, Childs BH, Yasuda M, Masuda S, Tsujino T, Terao Y, Tobinai K. Fukuhara N, et al. Int J Hematol. 2023 Jan;117(1):100-109. doi: 10.1007/s12185-022-03455-0. Epub 2022 Sep 29. Int J Hematol. 2023. PMID: 36175779 Free PMC article. Clinical Trial.
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL. Dreyling M, et al. J Clin Oncol. 2017 Dec 10;35(35):3898-3905. doi: 10.1200/JCO.2017.75.4648. Epub 2017 Oct 4. J Clin Oncol. 2017. PMID: 28976790 Clinical Trial.
31 results